Ann: CLARITY 2.0 COVID-19 Study Concludes Recruitment, page-16

It really is very difficult to imagine a meaningful outcome in just 49 patients based on an 8 point
Clinical Health score given the well now placebo effect and other potential con founders.

I’m afraid although REMAP and Clarity involved little cost to DIMERIX (being just supply of drug and staff time) and that they were initiated or envisaged in the difficult early days of the pandemic when any feasible idea seemed worth pursuing, they have both turned out disappoint.

DIMERIX have one Phase 3 study, ACTION 3, and this has yet to report its first dosed patient.